Mallinckrodt Hospital Products IP Limited

Mallinckrodt Pharmaceuticals Ireland Limited

Mallinckrodt Pharma IP Trading D.a.c.

Ino Therapeutics Gmbh

Mallinckrodt Hospital Products IP Unlimited Company

Jim Potenziano

Joseph J Medicis

Jaron Matthew Acker

David William Newman

Craig Flanagan

Jeff Griebel

Lisa Cooper

Eddie Costa

Douglas R Hansell

Craig R Tolmie

Jeffrey Schmidt

Robert Schnitman

James Baldassarre

Douglas Stuart Greene

Douglas Alan Greene

Ronald Bronicki

Brahm Goldstein

Khurram Jamil

Stephen Chris Pappas

Joe Stauffer

The present disclosure provides methods to improve the viability of an organ, or organs, by continuously administering a composition comprising NOgas directly to the organ(s).

Methods to improve organ viability

Described is an apparatus for monitoring nitric oxide delivery, wherein such apparatus comprises a display that provides a visual and/or numeric indication of the calculated dose of nitric oxide. Also described is a method of monitoring nitric oxide delivery, wherein the breathing gas flow rate and therapeutic gas flow rate are measured and used to determine the calculated dose of nitric oxide, which is then displayed. In some embodiments, an alert is provided when the calculated dose rises above or falls below a predetermined level or range.

Apparatus and method for monitoring nitric oxide delivery

Described are systems and methods for monitoring administration of nitric oxide (NO) to ex vivo fluids. Examples of such fluids include blood in extracorporeal membrane oxygenation (ECMO) circuits or perfusion fluids used for preserving ex vivo organs prior to transplanting in a recipient. The systems and methods described herein provide for administering nitric oxide to the fluid, monitoring nitric oxide or a nitric oxide marker in the fluid, and adjusting the nitric oxide administration.

Administration and monitoring of nitric oxide in ex vivo fluids

Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.

Method of identifying and treating premature infants at risk for BPD

Disclosed are methods of treatment that permit a reduction of risk of mortality in infants who are candidates for treatment with inhaled nitric oxide, by identifying a subset of such infants who are at an increased risk of mortality upon treatment with inhaled nitric oxide; also disclosed are related systems for use in administering inhaled nitric oxide and methods of distributing a pharmaceutical product.

Methods of reducing the risk of mortality associated with a medical treatment

Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.

Use and monitoring of inhaled nitric oxide with left ventricular assist devices

The present invention relates to a device and method of delivering inhaled Nitric Oxide (iNO) to a patient situated in a Magnetic Resonance Imaging (MRI) suite.

Gas delivery device and system for use in magnetic resonance imaging

Described is an apparatus for monitoring nitric oxide delivery, wherein such apparatus comprises an indicator to inform a user of the apparatus when the flow of breathing gas rises above or falls below a predetermined level or range. Also described is a method of monitoring nitric oxide delivery, wherein the flow of breathing gas is measured and displayed. In some embodiments, an alert is provided when the flow of breathing gas rises above or falls below a predetermined level or range.

Growing community of inventors

Binghamton, NY, United States of America

Jim Potenziano